Staff Profile
Helen Mossop
Biostatistician (Research Associate)
- Email: helen.mossop@ncl.ac.uk
- Address: Population Health Sciences Institute
Faculty of Medical Sciences
Newcastle University
Publications
- Giles EL, McGeechan GJ, Coulton S, Deluca P, Drummond C, Howel D, Kaner E, McColl E, McGovern R, Scott S, Stamp E, Sumnall H, Todd L, Vale L, Albani V, Boniface S, Frankham J, Ferguson J, Gilvarry E, Hendrie N, Howe N, Mossop H, Ramsay A, Stanley G, Newbury-Birch D. Brief alcohol intervention for risky drinking in young people aged 14 15 years in secondary schools: the SIPS JR-HIGH RCT. Public Health Research 2019, 7(9).
- Dutta P, Funston W, Mossop H, Ryan V, Jones R, Forbes R, Sen S, Pearson J, Griffin SM, Smith J, Ward C, Forrest IA, Simpson AJ. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax 2019, 74(4), 346-353.
- Forbes R, Ased A, Abouhajar A, Brennand C, Brown H, Carnell S, Chadwick T, Eardley I, Lecouturier J, Mossop H, Pearce I, Pickard R, Thiruchelvam N, Walton K, Wilkinson J, Harding C. ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic patient‐randomised non‐inferiority trial. Trials 2018, 19, 616.
- Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology 2016, 17(8), 1047-1060.
- Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Rodrigues DN, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, deBono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine 2015, 373(18), 1697-1708.
- Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology 2015, 16(16), 1605-1616.